US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.01 against a street estimate of 0.02 — a miss of 150.0%.
Analysts rate Xeris Pharmaceuticals Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $12.86.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.97% |
| D. E. Shaw & Co LP | 4.28% |
| Vanguard Capital Management, LLC | 4.03% |
| State Street Corp | 2.64% |
| Geode Capital Management, LLC | 2.59% |
| Nuveen, LLC | 2.41% |
| Rosalind Advisors, Inc. | 1.60% |
| Qube Research & Technologies | 1.59% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue was $107,225,000, up from $74,380,000 in the third quarter of 2025. • Nine-month 2026 total reve | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue rose 44% year over year to $107.2 million, including $106.3 million of product revenue. • Net income w | 2026-11-05 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Xeris Biopharma Holdings appointed Menassie Taddese to its Board of Directors, effective November 2, 2026. • The Board increa | 2026-11-02 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 13, 2026, Xeris Biopharma Holdings, Inc. filed two patent infringement lawsuits in the U.S. District Court for the Dist | 2026-10-14 |
| Reg FD disclosure · Q3 2026 XERIS BIOPHARMA HOLDINGS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or numerical results disclosed | 2026-09-09 |
| Quarterly report · Q2 2026 XERIS BIOPHARMA HOLDINGS, INC. — Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $175.2 million, up 33% vs. $131.7 million in | 2026-08-06 |
| Results announced · Q3 2026 XERIS BIOPHARMA Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $92.1 million, up 29% year-over-year from $71.5 million • Net pro | 2026-08-06 |
| Company announcement · Q3 2026 XERIS BIOPHARMA HOLDINGS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Approximately $23 million in convertible debt exchanged for 5.0 million common | 2026-07-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xeris Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.